MEN 1 Endocri JB Flashcards
(38 cards)
How much calcium would you consume from the 1000g intake
300mg, of which, 125mg will be excreted.
in the body, there are pools of up to 900mg of calcium in ECF, 1000mg in bone.
Absorption through GIT is mediated via active vitamin D
how does PTH mediate calcium homeostasis?
PTH action includes:
RENAL
- calcium reabsorption from distal tubule
- Inhibition of proximal tubule phosphate reabsorption
- Proximal tubule synthesis of 1,25 Vitamin D3
SKELETAL
- PTH stimulates osteoclastic bone resorption GIT
- 1,25 Vitamin D stimulates small intestinal receptors, increasing the absorption of calcium
Explain CALCIUM HOMEOSTASIS
alterations in extracellular calcium result in short and long term changes in PTH.
- ther eis an inverse sigmoid relationship between PTH secretion and extracellular calcium.
- Extracellular calcium concentration producing 50% maximal PTH provides a ‘set point’ for calcium.
- Elevations in set point seen in primary hyperparathyroidism and FHH
What are the clinical manifestaitions of hypercalcemia
Non specific: anorexia, abdo pain, constipation, lethargy, headache, altered mentation, depression.
Organ specific:
- Gastrointestinal: constipation, pancreatitis
- Renal: calculus, RTA, chronic hypercalcaemic nephropathy
- Neuropsychiatric and neuromuscular:
- CVS: hypertension
how do we classify hyperparathyroidism?
Classification is based on the level of PARATHYROID HORMONE PTH
- PTH dependent: primary hyperparathyroidism - > most PHPT associated with callcium <3.0mmol
- PTH independent (malignancy, Vit D excess)
How do we assess hyperparathyroidism?
Measure PTH paired with calcium
- If PTH non suppressed = primary hyperparathyroidism
: MUST exclude FAMILIAL HYPOCALCIURIC HYPERCALCEMIA.
- If PTH is suppressed then it is non-parathyroid mediated:
- neoplasia (PTHrp, osteolytic mets)
- Vitamin D excess (exogenous, granulomatous)
- Thyroxtoxicosis, adrenal insufficiency
- Thiazide diuretics etc
WHAT IS PRIMARY HYPERPARATHYROIDISM
CHARACTERISED BY RAISED CALCIUM AND NON SUPPRESSED PTH
- 1:500 general population
- Increasing age, F>M
- 90% due to solitary parathyroid adenoma, carcinoma is extremely rare
- 5% of all gland hyperplasia due to MEN1 and chronic renal disease.
- Complications include nephrolithiasis, osteoporosis, neuromuscular and ?
increased CVD mortality
- Rate of disease progression is variable -> may be minimal in post-menopausal women with mild hypercalcemia.
Hwo do we manage primary hyperparathyroidism?
- observe if mild, asymptomatic biochemical disease in the elderly female.
- HRT? in post menopausal women
- At risk patients: parathyroidectomy
- Interim medical therapy for moderate to severe hypercalcemia (>3.5,mmol)
- Rehydration, bisphosphonates
- Calcimimetric agents (calacalcet) for PTH mediated hypercalcemia
What are indications for surgeyr in PHPT
Overt risk of complications: nephrolithiasis, renal impairment, parathyroid bone disease, neuromuscular disease, previous life threatening hypercalcemia
High risk of complications: serum calcium >3mmol/L, urine calcium >10mmol/day, reduced BMD
Other: age <50
WHAT ELSE WOULD YOU CONSIDER IN APPARENT PHPT
- familial hypocalciuric hypercalcemia
- parathyroid hyperplasia (5%) PHPT (sporadic, MEN, familial isolated hyperparathyroidism)
What is FHH?
Disorder of extracellular Ca2+ sensing due to CaR mutations (multiple described). Characterised by lifelong mild-moderate (1.5mmol/l) asymptomatic hypercalcemia
- Elevated set point for calcium regulation PTH release (ie. for any given level of serum calcium, FHH patients have higher concentrations of PTH than normal.
– Autosomal dominant, high penetrance and significant phenotypic variability
– Hypercalcaemia accompanied by low urinary calcium and inappropriately normal
serum PTH Serum 25OHD, 1,25OH2D3 normal
– Generally considered benign (no nephrolithiasis), however older patients with FHH show high prevalence of chondrocalcinosis, possible increased risk of pancreatitis
20% of patients with advanced malignancy can experience hypercalcemia of malignancy. why?
- Osteolytic metastases (breast and non-small cell lung cancer)
::: Local cytokine mediated (TNF, IL-1) - Osteoclast activating factors (multiple myeloma, lymphoma)
::: Circulating cytokine mediated (TNF, IL-1, IL-6) - Excess calcitriol (1,25 Vit D) (lymphoma and granulomatous disease)
- PTH-related peptide (PTHrP) (particularly non-metastatic solid tumours)
PTH related peptid (PTHrP)
- PTHrP Has N terminal homology with PTH.
: Developmental hormone (cartilage, breast)
: Placental function, lactation
: humoral hypercalcaemia of malignancy (80% of hypercalcemia associated with solid tumours)
– PTH / PTHrp receptor mediated PTHrP action
How do you treat non PTH mediated hypercalcemia
Treatment: obserrve if mild biochemical disease and treat underlying disorder
- interim medical therapy for moderate - severe hypercalcemia (>3.5mmol/L calcium)
- rehydration and bisphosphonates
- Saline diuresis with frusemide
- Blind CaR and suppress the PTH release
- Glucocoritcoids- granulomatous of lymphomatous hypercalcemia
- Calcitonin dialysis, mithramycin, gallium nitrate etc.
What causes:
- secondary hyperparathyroidism?
- tertiary hyperparathyroidism?
Secondary HPT: decreased calcium results in an appropriate rise in PTH.
Tertiary HPT: chronic parathyroid overstimulation in renal disease leads to parathyroid hyperplasia and hypercalcemia
What is Multiple Endocrine Neoplasia type 1? what are other names for it?
MEN1, Wermer’s Syndrome, MEA1
- AUTOSOMAL DOMINANT disease: tumour suppressor gene on chromosome 11q; high penetrance (95% by the age 30)
- 2 per 100,000
- Identified in all major racial groups
- Considered to have a PPP PHENOTYPE:
- PARATHYROID
- ENTEROPANCREATIC
- PITUITARY neoplasia
Spectrum of the MEN1 Phenotype
Large- can invade pretty much anything and everything.
Parathyroid Pancreatic Pituitary Adrenal Gastroduodenal Thymus Bronchus Thyroid Subcutaneous Skin Smooth muscle CNS
What is the MEN1 gene?
Tumour suppressor gene on chromosome 11q with high penetrance.
encodes a 610 aa product that behaves as a transcriptional co represor for genes associated with cell growth.
- >80% of mutations predict a loss of function (c/wTSG): >200 mutations identified to date, some intronic
- Numerous polymorphisms not associated with MEN1
- 10-20% of families do NOT have an identifiable mutation
What is the MEN1 disease spectrum?
Endocrine Tumours: benign or malignant
Non endocrine mesenchymal tumours
What is the MEN1 disease spectrum?
- a: benign and malignant endocrine tumours
Benign
- Parathyroid hyperplasia >95%
- Pituitary Adenoma 20-50%
- Adrenal macronodular hyperplasia 25%
Malignant potential
- Gastro-enteropancreatic NET’s (gastrin, glucagon) ; 30-50%
- “non functioning” pancreatic adenoma 50-80%
- Bronchial carcinoid <5%
What is the MEN1 disease spectrum?
b: non endocrine mesenchymal tumours
- skin (angiofibroma, collagenomas, macules) >80%
- leiomyomas (uterine, oesophageal, lung) ?20%
How do we diagnose MEN1
Familial :
- MEN1 gene identified, family history and one characteristic disorder, obigate carrier
Non familial MEN1:
- synchronous and metasynchronous presence of 2 or more characteristic disoders
- a well defined family history of mutation is absent
Hyperparathyroidism in MEN1
hyperparathyroidism is usually the FIRST MANIFESTATION in MEN1
Develops in >95% of gene characters by the age of 30.
Early treatment is important for even MILD hypercalcemia.
‘non functioning’ pancreatic adenoma in MEN1
- Develop in up to 70% of gene carriers (up to 40% by age 20)
- Commonly multi-focal and clinically
- Resect if large or rapidly enlarging